Pneumonia Diagnostics Market Poised to Worth US$ 685 Mn by 2027 End – Future Market Insights
The World Health Organization estimates that pneumonia accounted for 16% of all deaths of children below the age of 5 years – more than 920,000 in 2015. The WHO states that the cost of pneumonia antibiotic treatment in the same year for child survival and newly born babies is roughly US$ 110 million annually. Therefore, there is a pressing need to analyse the pneumonia diagnostics market. In an upcoming report titled ‘Pneumonia Diagnostics Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027′, Future Market Insights has undertaken a comprehensive study of the pneumonia diagnostics market that is poised to be worth more than US$ 685 million in 2027.
Product Type – Focus on Streptococcus-based and Viral Pneumonia-based Product Types
The streptococcus-based product type is the largest in the pneumonia diagnostics market at the end of 2016 and is unlikely to fall behind anytime soon. The streptococcus-based segment is the only one worth more than US$ 100 million in 2017 alone. Streptococcus-based pneumonia is considered an invasive form of the infection with an incidence of 10 to 100 cases per a population of 100,000.
Request to View Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2970
The viral pneumonia- based segment is predicted to witness the highest CAGR in the pneumonia diagnostics market over the course of the decade. The viral pneumonia segment of the pneumonia diagnostics market should cross US$ 180 million by end 2027, making it well worth the while of major stakeholders. Viral-based pneumonia is thought to cause approx. 8% of all cases of community-acquired pneumonia in the cases where patients required hospitalization.
Region – North America and Western Europe Vital in Pneumonia Diagnostics Market
North America has the maximum share in the pneumonia diagnostics market and is on track to retain this share for some time. The US, primarily due to its world-class healthcare infrastructure and a geriatric population susceptible to pneumonia, represents a larger opportunity than Canada in the North America pneumonia diagnostics market. In addition to this, there is high awareness about pneumonia and its debilitating effects on both infants and the elderly. The North America pneumonia diagnostics market is expected to just push past US$ 200 million by the end of the forecast period.
Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-2970
Western Europe follows North America in the pneumonia diagnostics market with Germany and the UK comprising the bulk of the regional market. The two behemoths represent more than 40% of the Western Europe pneumonia diagnostics market between themselves and companies are advised to focus their attention there. The Western Europe pneumonia diagnostics market is anticipated to record a robust CAGR of 6.2% from 2017 to 2027, making it a region too lucrative to ignore in the global pneumonia diagnostics market. The market attractiveness of Germany is much higher than that of the UK at 1.6.
Competition Dashboard in the Pneumonia Diagnostics Market
Prominent companies profiled in the pneumonia diagnostics market report include Thermo Fisher Scientific, Alere, Quidel Corporation, Becton Dickinson and Company, Meridian Bioscience, Qiagen N.V., bioMérieux SA, Bio-Rad Laboratories Inc., Cardinal Health Inc., and Beckman Coulter Inc.
Pneumonia Diagnostics Market Taxonomy
- Viral Pneumonia-based
- Mycoplasma Pneumonia-based
- North America
- Western Europe
- Eastern Europe
- Latin America
- Asia Pacific Excluding Japan
- Middle East & Africa
Changing global demographics coupled with greater medical awareness increase the potential for companies in the pneumonia diagnostics market. Manufacturers are seeking to introduce rapid diagnostics to exploit untapped opportunities and producers of pneumonia diagnostics have expanded the value chain to forward integrate the market in emerging economies. A high return on investment could be realized by shifting manufacturing from traditional culture techniques to rapid diagnostics at the point of care.
Request to View TOC of the Report @ https://www.futuremarketinsights.com/toc/rep-gb-2970
More from FMI’s Healthcare, Pharmaceuticals and Medical devices Intelligence:
- Dermatology Devices Market Segmentation By Product Type – Lasers, RF Devices and Microdermabrasion Devices, By Application – Vascular Lesions, Tattoo Removal, Hair Removal, Wrinkle Removal, Scar Removal and Acne Removal, By End User – Hospitals, Specialty Dermatology Clinics and Private Clinics
- Central Venous Catheter Market Segmentation By Product Type – Tunnelled Catheters and Non-Tunnelled Catheters, By Property – Antimicrobial Catheters and Non Antimicrobial Catheters, By Design – Single Lumen, Double Lumen and Multi Lumen, By Composition – Polyurethane, Polyurethane / Poly Carbonate and Silicone
- Intraosseous Infusion Devices Market Segmentation By Product Type – B.I.G (Bone Injection Gun), FAST1, EZ-IO, FAST Responder, Intraosseous Needles, Others; By Technology – Manual, Automatic; By End User – Emergency Medical Services, Hospitals, Ambulatory Surgical Centres, Cardiac Care Centres; By Route of Administration – Sternum, Distal & Proximal Tibia, Distal Femur, Calcaneus, Head of Humerus
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com
Press Release Source: https://www.futuremarketinsights.com/press-release/pneumonia-diagnostic-market